Taking Psychedelics Seriously
Ira Byock
Journal of Palliative Medicine January 22, 2018 DOI: 10.1089/jpm.2017.0684 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Anxiety Psilocybin |
| Keywords | Terminally ill Palliative care Depression economics Compassionate use Psychotherapist Hallucinogen Nursing Clinical trial |
| Citations | 164 |
| Key points | Argues that political, regulatory, and industry challenges impede the legitimate use of psychedelics, and that it is time to revisit their therapeutic use given precedents for access to unapproved medications and acceptance of physician-hastened death. |
Abstract
Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access program and right-to-try laws in multiple states provide precendents for giving terminally ill patients access to medications that have not yet earned FDA approval. Given the prevalence of persistent suffering and growing acceptance of physician-hastened death as a medical response, it is time to revisit the legitimate therapeutic use of psychedelics.
Comparable studies
Other theoretical and historical papers on psilocybin for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelics as Medicines: An Emerging New Paradigm General population | 2016 | Theoretical or philosophical paper | |
| Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy | 2022 | Theoretical or philosophical paper | |
| The Heffter Research Institute: Past and Hopeful Future | 2014 | Historical analysis | |
| Out of the box: A psychedelic model to study the creative mind | 2018 | Theoretical or philosophical paper | |
| Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa | 2021 | Theoretical or philosophical paper |